A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer

• 作者: Yuchen Guo Yangyang Zhou Wenxin Qin
• 来源期刊: 癌症生物学与医学（英文版）
• 年，卷（期）: 2022,（2）
• 所属期刊栏目: EDITORIAL
• 页码范围: 136-139
• 页数: 4页
• 语种: 英文
• DOI: 10.20892/j.issn.2095-3941.2021.0520

摘要

Recently, in cooperation with the Netherlands Cancer Institute, we demonstrated that epidermal growth factor receptor (EGFR) activation limited the response of liver cancer to lenvatinib. The original article was published in Nature as a cover story, which resulted in considerable attention from major scientific jour-nals.